The conference explores how real-world data (RWD) and artificial intelligence (AI) can transform drug development, regulatory and HTA decision-making, and ultimately drive value-based, patient-focused healthcare.
Medaffcon develops the Patient Dynamics tool based on customer feedback and user experience.
Patient Dynamics tool compiles up-to-date and regional data on medicine use in Finland and Sweden.
This Finnish registry-based study investigated the development of treatment practices and patient outcomes between 2013 and 2022.
Eliminating low-value care is a key means of safeguarding the sustainability and quality of healthcare.
Access times to medicines vary greatly between European countries, and delays in oncology drugs in particular are increasing.
A Nordic approach to data collection carried out through Medaffcon saves clients’ resources, reduces duplicate work, and accelerates processes.
Target Trial Emulation does not replace randomized controlled trials, but it applies their logic and rigor to real-world data analysis.
The data team keeps Medaffcon's research projects on track and ensures that the research findings are scientifically sound. At the heart of the team’s work is the processing and analysis of patient data, particularly in Real-World Evidence (RWE) studies.
Medaffcon's European Lung Cancer Congress (ELCC) poster showcased key findings from a recent study on non-small cell lung cancer (NSCLC).
Johan Rehnberg started working as a Scientific Advisor at Medaffcon’s Swedish office in August 2024. He is a dynamic researcher who values opportunities to learn new things and develop his skills – opportunities that Medaffcon provides.
The algorithm was originally developed to extract smoking status from patient texts with purpose to analyze the effects of smoking on postoperative complications. Today, it is also being utilized in lung cancer research.
Asthma and antibiotic use are linked to a higher risk of revision surgery in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). This finding is based on a real-world evidence (RWE) study published in February.
A real-world evidence (RWE) study on the treatment of metastatic castration-resistant prostate cancer (mCRPC) has provided new insights into the therapeutic strategies for mCRPC. The analysis was based on data from 2,500 patients treated in Finland.
The lymphoma research project has proven to be an exceptionally versatile source of new knowledge. The project includes at least two doctoral researchers, and its results are expected to generate well over ten scientific articles.
Multiple myeloma significantly increases the risk of infections. A recent real-world evidence (RWE) study revealed that multiple myeloma (MM) patients experience more infections compared to healthy controls, even prior to diagnosis. Infections, both before and after diagnosis, were associated with an increased mortality.
5th Nordic RWE and AI conference is organized by University of Helsinki and Åbo Akademi University. Register to the event here!
Despite its high-risk nature and availability of kidney treatments, chronic kidney disease (CKD) often goes undiagnosed. This especially concerns patients without type 2 diabetes (T2D), who represent the majority of CKD patients. This finding comes from a recent registry study published in Nephrology Dialysis Transplantation (NDT).
Artificial intelligence (AI) is transforming research and working life across various industries. But what is its significance in health data analysis and real-world evidence (RWE) research? Medaffcon’s experts, Juhani Aakko and Lisse-Lotte Hermansson, share their perspectives on AI in their work.
Patient-centricity was one of the key themes at ISPOR Europe in Barcelona this November. Participants also discussed topics such as the use of Real-World Evidence (RWE) in Health Technology Assessment (HTA) and the significance of artificial intelligence. In this article, Medaffcon's ISPOR attendees share the most important themes from this year's event.
Medaffcon's operations in Sweden are well-established and growing, offering pharmaceutical companies RWE studies and Market Access services delivered by Data Scientists, Market Access experts, and RWE specialists working together.
The prognosis for patients with multiple myeloma (MM) has improved as treatments have advanced, but the disease remains incurable. The prevalence of the disease is increasing in Finland as the population gets older. This is evident from a recently published nationwide retrospective study based on real-world evidence (RWE).
The adoption of new diabetes medications in Finland was active between 2012 and 2019, according to an RWE (Real World Evidence) study published in May 2024. The study was conducted by Medaffcon in collaboration with the pharmaceutical company Sanofi.
In the coming years, breakthroughs in neurological and psychiatric drug research are expected to change treatment practices and significantly improve patients’ quality of life.
Medaffcon experts are versatile professionals who adapt to customer needs. In this article, one of them, Liisa Ukkola-Vuoti, a senior scientific advisor at Medaffcon, describes her work over two weeks. Liisa is also one of the writers for the Health Data Site by Medaffcon.
Lung cancer is the leading cause of cancer deaths in Finland, with a particularly poor prognosis for non-small cell lung cancer (NSCLC). It is often diagnosed at an advanced stage when treatment options are limited. A recently published retrospective registry-based real-world evidence (RWE) study on KRAS-mutated NSCLC patients in Finland addressed this issue.
Finland will become an even more attractive place for conducting RWE (real-world evidence) research when it becomes a seamless part of the European Health Data Space (EHDS). Thus, health data can be used more efficiently across the European Union (EU), and datasets can be combined on an EU-wide basis.
Hospital data lakes offer clinicians diverse real-world data (RWD) that supports their work. Dr. Heikki Ekroos, Chief Physician of Pulmonary Diseases at Helsinki University Hospital (HUS) Porvoo Hospital, presented real-world evidence (RWE) studies that were based on HUS data lakes data at Medaffcon’s EMMA client event.
Real-world data (RWD) created in Finnish healthcare is comprehensive and high-quality. Sweden, another Scandinavian country, also offers high-quality healthcare data for real-world evidence generation.
Pharmaceutical companies should consider Finland when evaluating locations for Real-World Evidence (RWE) studies. The country boasts numerous strengths that make it an outstanding choice for real-world data-based (RWD) research. “Finland’s strong tradition and extensive experience in utilizing healthcare registries for research make it unique,” says Dr. Riikka Mattila, Scientific Advisor at Medaffcon.
Selecting the right interactions is a key factor for success. Therefore, the client should also consider how well the partner understands the pharmaceutical industry's needs. When the partner has extensive hands-on experience from the industry, these irreplaceable insights enable the partner to guide the project at different strategic levels, ensuring that the client’s various needs can be identified and met.
My list of publications includes over 20 peer-reviewed scientific articles. One of them is a special one because the Finnish Current Care Guidelines mention it for heart failure. This blog discusses the impact of research by Medaffcon on treatment practices.
A study published in January 2024 in the Scandinavian Journal of Gastroenterology has revealed that the treatment of adults with Short Bowel Syndrome (SBS-IF) clearly has significant room for improvement.
Sweden's publicly funded healthcare system and universal access to specialized health care make the data derived from Sweden broadly generalizable, covering diverse populations including different ethnic backgrounds.
Our latest multiple myeloma publication describes how complex multiple myeloma treatment patterns were assembled from data available in the Helsinki University Hospital data lake, Finland, how the treatments have changed in 2013–2019, and what the estimated treatment costs are in multiple myeloma.The study published online in October 2023 was carried out by the experts at Medaffcon Oy, Sanofi Oy, and Helsinki University Hospital, Finland.
Utilising the data lake of the Hospital District of Southwest Finland (TYKS), Medaffcon, Pfizer and TYKS have examined the clinical adoption of new medications for advanced renal cell carcinoma and the utility of data extracted without extensive manual extraction.
Hospital data lakes are a central source of information in Medaffcon's studies, and often, data retrieval can be automated. However, what happens when more complex matters need to be extracted from the databases? In such cases, manual extraction is used, says Medaffcon's Scientific Advisor, Riikka Mattila
Swedish real-world health data, a recent addition to the in-house capabilities of Medaffcon, offer unique possibilities for measuring disease burdens and determinants, the effects of different exposures, and the outcomes of various health conditions in a population of almost 10.5 million people.
Real-world data (RWD) can, however, be utilised also in a variety of non-clinical medical and pharmaceutical studies to compare aspects such as treatment outcomes and resource utilisation between different geographies and treatment options, reminds Samuli Tuominen, senior data scientist at Medaffcon.
AstraZeneca Finland, Medaffcon and clinical experts have investigated what is the rarer endotype of severe asthma using biomarker data obtained from the data lake of Turku University Hospital (TYKS), Auria.
Samuli Tuominen, senior data scientist at Medaffcon, has co-authored a study that utilised propensity-score matching to compare the performance of two immunosuppressive drugs in patients with primary sclerosing cholangitis after liver transplantation. Medaffcon has helped to validate the superiority of tacrolimus over cyclosporine as a post-liver transplantation immunosuppressive regimen for patients with primary sclerosing cholangitis, a rare immune-mediated cholestatic liver disease.
Dr. Essi Havula has done an impressive international career as a researcher and top scientist. She joins Medaffcon team to strengthen the scientific possibilities of utilizing real-world-data and evidence.
Experts at Medaffcon have perused volumes of real-world data on patients with atopic dermatitis to provide new insights into co-morbidities and treatment patterns associated with the chronic skin condition.
Experts from Medaffcon, Takeda and the Hospital District of Helsinki and Uusimaa (HUS) have concluded an extensive study into paediatric short-bowel syndrome based on information from patient records.
Sweden’s abundance of high-quality digital healthcare data has enabled what is surely one of the most exhaustive study of mortality associated with Clostridioides difficile infections (CDI) in the world.